A review of findings from a major 2024 HIV conference described new evidence linking neuropsychiatric complications in people with HIV to brain inflammation, blood vessel disease, and genetic risk factors for Alzheimer's disease. Among therapeutic highlights, clinical trial data on tesamorelin — a peptide used to reduce visceral fat in HIV patients — and telmisartan were presented. The review also noted growing evidence of ongoing HIV activity in the brain even when viral loads in blood are suppressed.
Corley, Michael J; Letendre, Scott L; Nightingale, Sam